Ibandronovy kislota-Vista tab. of p/o of 150 mg No. 3 ***

Tablets of Ibandronovaya kislota-Vista are shown for treatment of osteoporosis at women during the post-menopausal period with the increased risk of changes. Reduction of risk of vertebralny changes is shown, the efficiency on prevention of fractures of neck of a hip is not established.

Structure

Active ingredient: ibandronic acid;

1 tablet, coated, contains ibandronovy acid 150 mg in the form of sodium of the ibandronat of monohydrate of 168.75 mg;

Excipients: lactose monohydrate, cellulose microcrystalline krospovidon (type A); silicon dioxide colloidal, the sodium stearylfumarating;

Film cover (Opadry II white): polyvinyl alcohol, titan dioxide (E 171), talc, macrogoal 3350.

Contraindication

• Hypersensitivity to ibandronovy acid or to any other component of drug.
• Hypocalcemia.
• Disease of a gullet with delay of depletion of a gullet, for example, a stricture, an achalasia.
• Inability to be in vertical position (to stand or sit) within not less than 60 minutes.

Route of administration

Tablet entirely, washing down with 1 glass of usual water (180-240 ml), sitting or standing in vertical position. It is not necessary to apply water with high concentration of calcium. If there are fears of rather potentially high levels of calcium in water (hard water), it is recommended to use bottled water with the low content of mineral substances.

to Patients should not lie within 60 minutes after administration of drug.

should Wash down medicament only with usual water.

to Patients should not chew or suck a tablet because of a possibility of formation of ulcers on mucous stomatopharynxes.

Feature of use

Pregnant

it is not applied.

Children

it is not applied.

Drivers

does not influence.

Overdose

Specific information on overdose treatment.

However, considering the available knowledge of bisfosfonata, development of side reactions from upper parts of digestive tract (such as gastric disorders, dyspepsia, esophagitis, gastritis, ulcer) can be observed or a hypocalcemia. For binding of medicament it is necessary to appoint milk or antiacid means, and any side reactions it is necessary to treat symptomatic. Because of risk of irritation of a gullet it is not necessary to cause vomiting. Patients need to be in vertical position.

Side effects

• from the immune system: seldom - exacerbation of bronchial asthma is rare - reactions of hypersensitivity, is very rare - anaphylactic reactions / shock.
• from nervous system: often - a headache, sometimes - dizziness.
• from an organ of sight: seldom - inflammation of an eye.
• from digestive tract: often - an esophagitis, gastritis, a gastroesophageal reflux disease, dyspepsia, diarrhea, an abdominal pain, nausea sometimes - an esophagitis, including ulcerations of a gullet or a stricture and a dysphasia, vomiting, a meteorism; seldom - a duodenitis.
• from skin and hypodermic cellulose: often - rash.

Interaction

Bioavailability at oral administration of ibandronovy acid decreases in the presence of food. In particular, food, calciferous, including milk and other polyvalent cations (aluminum, magnesium, iron) can break medicament absorption that matches the results received in researches on animals. Therefore the medicament should be taken after night starvation (not less than 6 hours).

to Store

out of children's reach.

to Store

at a temperature not above 25 °C.

Expiration date - 3 years.